BioGenex
Accelerating the pace of precision medicine

DATA SHEET
Hsa-miR-126Probe

Catalog No.	Description
HM126-100	One vial of 0.650 ml of probe in hybridization buffer

Analyte Specific Reagent. Analytical and performance characteristics are not established.

Doc. No. 932-HM126-100 Rev : E
Date of release: 31-Jul-2024

Description
The Hsa-miR-126probe has been designed from mature human miR-126 sequence. This fluoresceinated probe is provided in a hybridization buffer for localization of miRNA in FFPE tissue by *In Situ* hybridization.

Specifications
The Hsa-miR-126 identifies mature miR-126 sequences in formalin-fixed, paraffin-embedded human tissues and/or freshly prepared frozen tissues by *in situ* hybridization. This probe does not react with normal human mRNA or nuclear DNA present in tissues.

Storage and Handling
Store the reagent at 2-8 °C. Do not freeze. Do not use the reagent after expiration date on vial. The reagent must be brought to room temperature before use. (Important! The presence of precipitates induces background staining).

Precautions:
For professional use. The probe contains formamide. Formamide is classified as a teratogen. Pregnant workers should keep exposure to a minimum. Avoid inhalation, ingestion, and contact with unprotected skin. If skin contact occurs, wash thoroughly with soap and water. For more information, refer to the Material Safety Data Sheet, which is available upon request.

Quality Control
Each lot of this micro RNA probe is tested by *In Situ* hybridization for Quality Control purposes. Refer to the BioGenex Quality Control Testing Conditions table for additional information.

References

1. Lorio MV and Croce CM. (2012). MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review.**EMBO Mol Med** 4, 143–159.

2. Chen PS, Su JL, and Hung MC. (2012). Dysregulation of Micro RNAs in cancer. **Journal of Biomedical Science**, 19:90.

3. Nuovo GJ. (2008). In situ detection of precursor and mature microRNAs in paraffin embedded, formalin fixed tissues and cell preparations. **Methods** 44,39–46.

4. Song R. et al. (2010). In situ hybridization detection of microRNAs.**Methods Mol Biol**. 629, 287-94.

5. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa. (2008). Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer.**J. Cancer Res.** 1;68(7),2094-105.

6. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massague(2008). Endogenous human microRNAs that suppress breast cancer metastasis.**J. Nature.** 10;451(7175):147-52.

7. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, Calin GA, Menard S, Croce CM. (2007).MicroRNA signatures in human ovarian cancer. **Cancer Res**15;67(18):8699-707.

8. Zhang J, Du YY, Lin YF, Chen YT, Yang L, Wang HJ, Ma D. (2008). The cell growth suppressor, mir-126, targets IRS-1.**BiochemBiophys Res Commun.** 5;377(1):136-40. Epub 2008 Oct 1.

9. Fish JE Santoro MM, Morton SU, et al. (2008). miR-126 Regulates Angiogenic Signaling and Vascular Integrity **Developmental Cell** 15, 272–284.

10. Hamada S, Satoh H,Fujibuchi W, et al. (2012). MiR-126 Acts as a Tumor Suppressor in Pancreatic Cancer Cells via the Regulation of ADAM9 **Mol Cancer Res**; 10(1); 3–10.

BioGenex Quality Control Testing Conditions

Parameter	Conditions used
Control Tissue	CERVIX, OVARY, PROSTATE, BREAST, INTESTINE (FB-HM126).
Tissue Type	Formalin-fixed, paraffin-embedded cancer tissues